Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia Excellence Forum

Advertisement

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Advertisement

Asher Chanan-Khan, MD
Videos
BTK Inhibitors vs BCL-2 Inhibitors as Frontline Therapy for Patients With CLL
11/14/2022
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in favor of BTK inhibitors over BCL-2 inhibitors for the frontline treatment of patients with CLL in a debate at the 2022 Lymphoma, Leukemia & Myeloma Congress.
Asher Chanan-Khan, MD, argues in...
11/14/2022
Oncology
Jan Burger, MD
Videos
New and Emerging Targeted Agents for CLL: A Review of Available BTK Inhibitors
11/14/2022
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses relevant genetic mutations in CLL which may influence treatment decisions and reviews safety and efficacy data on new and emerging targeted agents for these patients, focusing on BTK inhibitors.
Jan Burger, MD, discusses...
11/14/2022
Oncology
Anthony Mato, MD, PhD, Memorial Sloan Kettering Cancer Center
Videos
Impact of Venetoclax Discontinuation or Modification on Survival Outcomes Among Patients With CLL
06/28/2022
Anthony Mato, MD, PhD, highlights findings from a post-hoc analysis of the phase 3 MURANO trial, which explored the impact of venetoclax dose modification and early discontinuation on survival outcomes for patients with CLL.
Anthony Mato, MD, PhD, highlights findings from a post-hoc analysis of the phase 3 MURANO trial, which explored the impact of venetoclax dose modification and early discontinuation on survival outcomes for patients with CLL.
Anthony Mato, MD, PhD,...
06/28/2022
Oncology
Andrew Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
Videos
Zanubrutinib Plus Obinutuzumab and Venetoclax With MRD-Driven Discontinuation Shows Promise in CLL/SLL
05/14/2022
Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.
Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.
Andrew Zelenetz, MD, PhD,...
05/14/2022
Oncology
Dr Siddiqi
Videos
Successful Manufacturing of Lisocabtagene Maraleucel for Patients With CLL
04/18/2022
Tanya Siddiqi, MD, shares results and insights of the TRANSCEND CLL 004 study of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy for patients with CLL.
Tanya Siddiqi, MD, shares results and insights of the TRANSCEND CLL 004 study of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy for patients with CLL.
Tanya Siddiqi, MD, shares...
04/18/2022
Oncology
Dr Yang
Podcasts
Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL
04/06/2022
Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.
Shenmiao Yang, MD, highlights a multicenter, phase 3 trial comparing ibrutinib versus rituximab for advanced CLL/SLL, in which ibrutinib outperformed rituximab in all therapy outcomes.
Shenmiao Yang, MD, highlights a...
04/06/2022
Oncology
Dr Gale
Videos
Dr Gale Highlights Transplants, Cell Therapies for CLL
03/14/2022
Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.
Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.
Robert Peter Gale, MD, PhD, DSc...
03/14/2022
Oncology
Dr Burger
Videos
Dr Burger Overviews the Activation, Expansion of T Follicular Helper Cells in CLL
03/10/2022
Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.
Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.
Jan A. Burger, MD, PhD,...
03/10/2022
Oncology
Dr Lee
Videos
Dr Lee Reviews Cirmtuzumab and Ibrutinib in MCL/CLL
03/02/2022
Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.
Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.
Hun Ju Lee, MD, reviews a phase...
03/02/2022
Oncology
Dr Constantine Tam
Videos
Dr Tam Overviews Zanubrutinib Versus Bendamustine-Rituximab in CLL/SLL
02/24/2022
Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.
Constantine Tam, MD, overviews results from the phase 3 SEQUOIA study on zanubrutinib versus bendamustine-rituximab in patients with treatment-naïve CLL/SLL, presented at ASH 2021.
Constantine Tam, MD, overviews...
02/24/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement